INTRODUCTION
breast cancer
BREAST CANCER
Informed consent refers to the autonomous permission granted for an activity with the underlying premise that the individual fully comprehends what that activity entails.Disconcertingly, there is no globally accepted consensus on the definition of broad consent. Following guidance from the World Medical Association's 2016 ‘Declaration on Ethical Considerations regarding Health Databases and Biobanks’,Undoubtedly research participants should serve an integral role in this discussion, underscoring the need for qualitative research to guide the review and adaptation of broad consent templates and policies. Their concerns and information needs are key elements in accepting broad consent and data sharing in research.The primary aim of PRISMA was to investigate the potential value of risk‐tailored versus traditional breast cancer screening protocols in the Netherlands. Mammograms (∼67,000), questionnaire data (∼38,000 surveys), blood (∼10,100 samples) and/or salvia (∼600 samples) were collected from participants, resulting in a unique cohort and a large population‐based biobank. The PRISMA study is a rich source of health research data that can likely serve as a biomarker pipeline for more than breast cancer alone. However, the original informed consent obtained from participants was project‐specific (i.e., research into breast cancer), hindering its use within the wider research community. Reapproaching women for broadened consent for other research would expand and encourage using these data. Yet, to ensure transparency and participant autonomy, it is first critical to understand PRISMA participants' concerns and needs regarding broadened consent. Thus, the primary aim of our study was to qualitatively explore PRISMA participants' perceptions of data sharing and their information needs for broadened consent to optimize informed decision‐making and garner confidence in the PRISMA data sharing initiative.